The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer

Abstract

Despite higher rates of R0 resections achieved by NACT, survival of patients treated with NACT was inferior to survival of patients who underwent primary surgery. NACT should only be offered to patients with advanced epithelial cancer who are not candidates for primary surgery.